A multicenter, open-label, randomized, phase III study to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physician's choice in patients with advanced endometrial cancer

Vicky Makker, Nicoletta Colombo, Antonio Casado, Alessandro D. Santin, Émeline Colomba, David S. Miller, Keiichi Fujiwara, Sandro Pignata, Sally Baron‐Hay, Isabelle Ray‐Coquard, Ronnie Shapira‐Frommer, Kimio Ushijima, Jun Sakata, Kan Yonemori, Yong Man Kim, Eva Guerra, Ulus Ali Şanlı, Mary McCormack, Jie Huang, Alan D. Smith, Stephen J. O’Keefe, Lea Dutta, Robert Orlowski, Domenica Lorusso